八氢吡啶并〔1,2-A〕吡嗪-6-酮 | 151665-85-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌嗪基哌啶类
• 中文名称: 八氢吡啶并〔1,2-A〕吡嗪-6-酮
• 英文名称: octahydro-6H-pyrido[1,2-a]pyrazin-6-one
• 英文别名: octahydro-pyrido[1,2-a]pyrazin-6-one；Hexahydro-1H-pyrido[1,2-a]pyrazin-6(2H)-one；1,2,3,4,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-6-one
• CAS: 151665-85-9
• 化学式: C₈H₁₄N₂O
• 分子量: 154.212
• InChiKey: WLXFQWJYMRTINR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  八氢吡啶并〔1,2-A〕吡嗪-6-酮 在 copper(l) iodide 、 四(三苯基膦)钯 、 palladium on activated charcoal 、 氢气 、 三乙胺 、 N,N-二异丙基乙胺 、 三苯基膦 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl 6-oxo-7-[3-([1,2,4]triazolo[1,5-a]pyridin-8-yl)propyl]-3,4,7,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate
  参考文献：
  名称：

  WO2020051153A5

  摘要：

  公开号：

  WO2020051153A5
• 作为产物：
  描述：

  2-甲基吡嗪 在 palladium on activated charcoal 正丁基锂 、 氢气 、 二异丙胺 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， -78.0 ℃ 、413.68 kPa 条件下， 反应 61.17h， 生成 八氢吡啶并〔1,2-A〕吡嗪-6-酮
  参考文献：
  名称：

  Structure–activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs

  摘要：

  Structure-activity relationships on two novel potent cognition enhancing drugs, unifiram (DM232, 1) and sunifiram (DM235, 2), are reported. Although none of the compounds synthesised reached the potency of the parent drugs, some fairly active compounds have been identified that may represent new leads to develop other cognition enhancing drugs. An interesting result of this research is the identification of two compounds (13 and 14) that are endowed with amnesing activity (the opposite of the activity of the original molecules) and are nearly equipotent to scopolamine. Moreover, two compounds of the series (5 and 6) were found endowed with analgesic activity on a rat model of neuropathic pain at the dose of 1 mg/kg. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.10.025

文献信息

• [EN] GCN2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GCN2 ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2019148132A1

  公开（公告）日：2019-08-01

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• Benzimidazole compounds as ORL1-receptor agonists
  申请人：——

  公开号：US20020049212A1

  公开（公告）日：2002-04-25

  A compound of the formula: 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is unsubstituted, mono-, di- or tri-substituted (C 3 -C 11 )cycloalkyl or (C 3 -C 11 )cycloalkenyl or the like, A is unsubstituted (C 1 -C 7 )alkyl or (C 2 -C 5 )alkenyl, hydroxy-(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy-(C═O), or unsubstituted, mono-, di- or tri- substituted aryl, or aromatic-heterocyclic or the like, M is a covalent bond O, S, NH or the like, Y is 4- to 12-membered bicyclic-carbocyclic rings or 4- to 12-membered bicyclic-heterocyclic rings, or 5- to 17 membered spirocarbocyclic rings or 5- to 17-membered spiroheterocyclic rings or the like, Z 1 , Z 2 , Z 3 and Z 4 are hydrogen or the like, is disclosed. These compounds have ORL 1 -receptor agonist activity, and are thus useful as analgesics or the like in mammalian subjects.

  一种化合物的公式：1或其药学上可接受的盐，其中R1为未取代、单取代、双取代或三取代的（C3-C11）环烷基或（C3-C11）环烯基等，A为未取代的（C1-C7）烷基或（C2-C5）烯基、羟基-(C1-C4)烷基、（C1-C4）氧基-(C═O)，或未取代、单取代、双取代或三取代芳基、芳香杂环或类似物，M为共价键O、S、NH或类似物，Y为4-至12-成员双环碳环或4-至12-成员双环杂环，或5-至17-成员螺环碳环或5-至17-成员螺环杂环或类似物，Z1、Z2、Z3和Z4为氢或类似物。这些化合物具有ORL1受体激动剂活性，因此在哺乳动物主体中可用作镇痛剂或类似物。
• Substituted pyrrolo[1,2-A] pyrazines, compositions containing these, processes of making these, and uses thereof
  申请人：Neurotune AG

  公开号：US08334286B2

  公开（公告）日：2012-12-18

  The invention refers to compounds of general formula (I) wherein the R groups are, independently, H, C1-6alkyl, aryl, CF3; Y is CH2, C═O; X is bond, C═O, SO2, or C═N—CN; m is 0, 1; n is 0, 1; A is a heterocycle, or a phenyl group optionally substituted as defined in the specification. The compounds are active on chronic pain conditions of different origin; they can be administered alone or with other drugs. Most of these compounds are new. The invention include a process to prepare said compounds, and pharmaceutical compositions suitable for their administration to a patient.

  本发明涉及一般式（I）的化合物，其中R基团是独立的H，C1-6烷基，芳基，CF3; Y是CH2，C═O; X是键，C═O，SO2或C═N—CN; m为0，1; n为0，1; A是杂环或苯基，可选地在规范中定义的取代基。这些化合物对不同来源的慢性疼痛病症具有活性；它们可以单独或与其他药物一起使用。大多数这些化合物都是新的。本发明包括制备所述化合物的方法，以及适合于向患者施用的制药组合物。
• NITROGEN-CONTAINING BYCYCLIC COMPOUNDS ACTIVE ON CHRONIC PAIN CONDITIONS
  申请人：Ghelardini Carla

  公开号：US20110015200A1

  公开（公告）日：2011-01-20

  The invention refers to compounds of general formula (I) wherein the R groups are, independently, H, C 1-6 alkyl, aryl, CF 3 ; Y is CH 2 , C═O; X is bond, C═O, SO 2 , or C═N—CN; m is 0, 1; n is 0, 1; A is a heterocycle, or a phenyl group optionally substituted as defined in the specification. The compounds are active on chronic pain conditions of different origin; they can be administered alone or with other drugs. Most of these compounds are new. The invention include a process to prepare said compounds, and pharmaceutical compositions suitable for their administration to a patient.

  该发明涉及一般式（I）的化合物，其中R基独立地为H，C1-6烷基，芳基，CF3；Y为CH2，C═O；X为键，C═O，SO2或C═N—CN；m为0，1；n为0，1；A为杂环或苯基，可选地取代如说明书所定义。这些化合物对不同起源的慢性疼痛症状具有活性，它们可以单独或与其他药物一起使用。其中大多数化合物都是新的。该发明包括一种制备上述化合物的方法以及适用于其向患者的管理的制药组合物。
• Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10640486B2

  公开（公告）日：2020-05-05

  The present invention relates to compounds of general formula (I), wherein D1 to D3, -A-, n, R1, R2, Y1, L and y2 are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.

  本发明涉及通式(I)的化合物，其中 D1 至 D3、-A-、n、R1、R2、Y1、L 和 y2 的定义如权利要求 1 所述，这些化合物具有宝贵的药理特性，尤其是血浆钙激 素的抑制剂。这些化合物适用于治疗和预防可受血浆钙激酶抑制影响的疾病，如糖尿病并发症，特别是治疗与糖尿病视网膜病变和糖尿病黄斑水肿相关的视网膜血管通透性。